HGH fragment 176-191: what the research shows
- By Reed Calder
- Last reviewed Nov 16, 2026
- 30 studies and official documents checked
In short
HGH fragment 176-191 is the last 16 amino acids of human growth hormone, made in the lab as a peptide. The name covers more than one thing: the version one amino acid shorter, 177-191, used in most animal studies, and AOD-9604, which is 177-191 with a tyrosine added and differs from 176-191 only in its first amino acid. Vials, studies and web pages mix the three up.
When 176-191 itself was tested in normal rats in 1978, blood glucose rose briefly, insulin rose for longer, and at 5 nmol/kg insulin sensitivity fell (Ng and Bornstein, 1978). Later, 177-191 cut weight gain in obese mice, and AOD-9604 by mouth cut weight gain in obese rats by more than half, 15.8 g against 35.6 g (Natera et al., 1994; Ng et al., 2000 (AOD9604)). We found no study that gave the native 176-191 fragment to people. AOD-9604 was tested in about 900 people, and in its largest trial, about 500 adults over 24 weeks, weight loss beat placebo by less than 1 kg (2.2 lb); see the AOD-9604 page.
The FDA has approved neither one. The 2026 WADA list names both hGH 176-191 and AOD-9604 as banned growth hormone fragments.
EvidenceCellAnimalHumanrat and mouse studies; no study of the native fragment in people
You’ll often read that HGH fragment 176-191 burns fat without touching blood sugar or insulin, that it is growth hormone without the side effects, and that it is proven in clinical trials. This page covers which peptide is which, what was studied in rats, mice and cells, the usual claims checked, what the studies used, side effects, where it stands with the FDA and in sport, and what’s still unknown.
Names and forms you’ll see
| Name | What it is | Studied in people? |
|---|---|---|
| HGH fragment 176-191, hGH frag 176-191, “frag 176-191” | The last 16 amino acids of human growth hormone: F-L-R-I-V-Q-C-R-S-V-E-G-S-C-G-F, formula C78H123N23O22S2, 1,799.1 g/mol (PubChem CID 16131230; UniProt) | We found no study |
| hGH 177-191, AOD-9401 | One amino acid shorter, 15 in all, without the first phenylalanine: 1,651.9 g/mol. Most of the older animal studies used this one (PubChem CID 25078169; Ng et al., 2000 (AOD9401)) | We found no study |
| AOD-9604, Tyr-hGH 177-191 | The 177-191 sequence with a tyrosine added at the front, so it differs from 176-191 only in its first amino acid (tyrosine instead of phenylalanine), 1,815.1 g/mol (Cox et al., 2015; PubChem) | Yes, six trials and three pain trials. See the AOD-9604 page |
| LAT-8881, LAT8881 | The later developer’s name for AOD-9604, a synonym in the FDA’s registry (FDA GSRS) | Three pain trials |
| Human growth hormone, somatropin | The whole 191-amino-acid hormone, a prescription drug and a different compound from the fragment (UniProt) | Yes, approved for several uses |
CAS numbers
A CAS number is a substance’s chemical registry number. Some “research” vials list it in place of a name. A different number usually means a different form, such as a salt, or a different substance. Each number belongs to a different peptide. Suppliers sometimes list the wrong one under the name “HGH fragment 176-191”.
What it is
Human growth hormone, or hGH, is a protein of 191 amino acids. Its last 16, positions 176 to 191, read F-L-R-I-V-Q-C-R-S-V-E-G-S-C-G-F. The two cysteines at positions 182 and 189 are joined by a disulfide bond in the whole hormone (UniProt), and the fragment is made as a ring closed by the same bond (PubChem).
The numbers count positions in the hormone. The 177-191 version leaves out the first of the 16. AOD-9604 adds a tyrosine to the front of 177-191, which makes it 16 amino acids long, with a tyrosine where 176-191 has a phenylalanine. The two peptides differ by one oxygen atom (1,815.1 against 1,799.1 g/mol) (Cox et al., 2015; PubChem).
The names are often mixed up. The 2022 breast cancer study calls its peptide hGH fragment 176-191, but the sequence it lists, YLRIVQCRSVEGSCGF, is the AOD-9604 sequence (Habibullah et al., 2022). A 2026 review writes AOD9604 as “hGH 176-191” (Dominikowski et al., 2026).
The research started in the other direction from the way it is sold. Papers in 1978 and 1979 described the end of growth hormone as raising blood sugar in rats (Ng and Bornstein, 1978; Wade et al., 1979). By 1993 the 177-191 peptide was reported to block fat-making in rat fat tissue like the whole hormone does (Wu and Ng, 1993), and by 2000 a version was being developed as an “antiobesity drug”, the origin of the AOD name (Ogru et al., 2000).
What has been studied
We found no study that gave the native 176-191 fragment to people. PubMed lists 18 records that mention a growth hormone 176-191 or 177-191 fragment in the title or abstract (searched November 16, 2026); they are rat, mouse and cell studies, reviews and lab analyses. The tables below group them by which peptide was tested.
In normal and obese rats and mice, 1978 to 1994: 176-191 and 177-191
| Study | Model | What was used | What it found |
|---|---|---|---|
| Ng and Bornstein, 1978 | Normal rats | Synthetic hGH 172-191, 176-191, 177-191, 178-191, 179-191 and 180-191 | The first four raised blood glucose briefly and insulin for longer; the last two did nothing. At 5 nmol/kg the peptides containing 178-191 cut insulin sensitivity on an insulin tolerance test |
| Wade et al., 1979 | Live animals (the abstract does not say which) | Synthetic hGH 177-191, 178-191 and 179-191, made by solid-phase synthesis | Diabetogenic activity was tested. 179-191 needed extra amino acids at the front to work, and a form of 177-191 with the ring opened was also active, so the ring was not required |
| Wu and Ng, 1993 | Rat fat tissue | hGH 177-191 | Blocked fat-making as much as the whole hormone. There was no significant rise in glycerol release, the measure of fat breakdown |
| Wijaya and Ng, 1993 | Fat cells from obese Zucker rats | hGH 177-191, against whole hGH at equal amounts | Lowered glucose uptake, with or without insulin, and was more potent than the whole hormone |
| Natera et al., 1994 | Obese ob/ob mice, long-term treatment | hGH 177-191 | Less cumulative weight gain and less fat tissue; fat-making in fat tissue was significantly lower |
EvidenceCellAnimalHumanrats and mice; these tested 176-191 or 177-191, not AOD-9604
In rats and mice, 2000 to 2001: 177-191 and AOD-9604
| Study | Model | What was used | What it found |
|---|---|---|---|
| Ng et al., 2000 (AOD9401) | Rat fat tissue; obese Zucker rats for 20 days | AOD9401, the 177-191 peptide | It stimulated hormone-sensitive lipase and blocked a fat-making enzyme in fat tissue. Weight gain fell and fat cells shrank from 110 to 80 µm across. Unlike whole growth hormone, it caused no insulin resistance or glucose intolerance after long treatment |
| Heffernan et al., 2000 | Obese ob/ob mice, 30 days (8 on saline, 10 on the peptide); human fat tissue in a dish | AOD-9401 by mouth | Weight gain was lower from day 16, with no difference in food eaten. Fat tissue made less fat and broke down more, and energy use and fat burning rose briefly. The same fat-breakdown and anti-fat-making changes appeared in fat tissue from obese rodents and from people |
| Ng et al., 2000 (AOD9604) | Obese Zucker rats, 19 days | AOD-9604, 500 µg/kg a day by mouth | Weight gain was more than halved, 15.8 g against 35.6 g. Fat tissue broke down more fat. Insulin sensitivity was not worse on a euglycemic clamp |
| Heffernan et al., 2001 (mice) | Obese and lean mice, 14 days by pump | Whole hGH or AOD-9604 | Both reduced weight gain and raised fat burning. AOD-9604 did not raise blood sugar or cut insulin release as whole growth hormone did, did not bind the growth hormone receptor and did not make cells multiply |
| Heffernan et al., 2001 (receptor) | Obese mice, and mice lacking the fat-cell receptor beta-3 | Whole hGH or AOD-9604, 14 days into the abdomen | Both cut weight and fat. In mice without the beta-3 receptor, long treatment did not change weight, but an acute dose of AOD-9604 still raised energy use and fat burning |
EvidenceCellAnimalHumanobese rats and mice; effects on weight gain, not on existing weight
In people: AOD-9604, not the native fragment
| Study | Who | What was used | What it found |
|---|---|---|---|
| Six developer trials, 2001 to 2006 | About 900 adults, mostly with obesity | AOD-9604 as pills and single doses by vein, against placebo | The developer’s own scientists wrote the safety summary. It reports no significant IGF-1 or glucose differences (Stier et al., 2013) |
| The 24-week OPTIONS trial | About 500 adults with obesity | AOD-9604 tablets of 0.25, 0.5 or 1 mg a day, with a supervised diet and exercise program | Weight loss beat placebo by less than 1 kg (2.2 lb) at every dose, too little to reach statistical significance. The developer ended its obesity program on February 21, 2007 (company announcement, 2007) |
| Pain trials as LAT8881, 2019 to 2023 | Three small trials of 17 to 53 people with nerve pain, migraine, or back-and-leg pain | LAT8881 capsules or an infusion into a vein, against placebo | None beat placebo on its main pain measure (NCT03865953; NCT04153409; NCT05298306) |
The details, the FDA’s review and the safety signals are on the AOD-9604 page. They show what the 177-191-plus-tyrosine peptide did in people, not what 176-191 does.
EvidenceCellAnimalHumanAOD-9604 only; no human study of the native fragment
Cancer cells and rabbit knees
| Study | Model | What was used | What it found |
|---|---|---|---|
| Habibullah et al., 2022 | Human MCF-7 breast cancer cells, and computer docking | Chitosan nanoparticles loaded with doxorubicin and a peptide called hGH fragment 176-191 (the sequence listed is AOD-9604’s) | Cell survival fell at a lower concentration with the peptide: IC50 1.5 µg/mL, against 1.85 for doxorubicin alone and 1.7 for doxorubicin-loaded nanoparticles. The peptide alone in nanoparticles was not toxic to the cells. The authors report no conflicts of interest |
| Kwon and Park, 2015 | 32 rabbits with chemically induced knee arthritis | AOD-9604, 0.25 mg injected into the knee weekly, with or without hyaluronic acid | Cartilage damage scores were better than with saline, and best with AOD-9604 plus hyaluronic acid. Lameness was also scored. No human study |
EvidenceCellAnimalHumana cell and computer study and one small rabbit study; the peptide was AOD-9604
In lab analyses of the peptides and the products sold
| Study | What was tested | What it found |
|---|---|---|
| Cox et al., 2015 | AOD-9604 in serum and urine; vials confiscated in the U.S. | AOD-9604 was found in confiscated vials. Six breakdown products formed; one, CRSVEGSCG, was much more stable than the others |
| Mazzarino et al., 2026 | 54 prohibited compounds, including hGH 176-191 and AOD-9604, in blood samples | Both peptides were extensively degraded after a week in serum or plasma at 4 or 22 °C, and stayed detectable in dried samples. This measures storage of samples, not how long the peptide lasts in the body |
| Janvier et al., 2018 | The ten falsified peptide drugs most often found on the Belgian market, bought from internet pharmacies | Purity was 5% to 75% for peptides with cysteines, the amount per unit varied widely, and some samples held arsenic or lead. We did not verify whether this study included the fragment |
| Dominikowski et al., 2026 | A 2026 review of performance-enhancing peptides | For AOD-9604 it lists oral use and says no half-life was reported in human trials |
EvidenceCellAnimalHumanlaboratory analyses; not studies of effects in people
The usual claims, checked
| Claim | Verdict | What the studies found |
|---|---|---|
| HGH fragment 176-191 burns fat | Untested | We found no study in people. In obese mice 177-191 cut weight gain and fat tissue, and AOD-9604 cut weight gain in rats. The 24-week AOD-9604 trial beat placebo by less than 1 kg, or 2.2 lb (Natera et al., 1994; Ng et al., 2000 (AOD9604); company announcement, 2007) |
| It removes belly fat | Untested | We found no study of belly or visceral fat in people given the fragment or AOD-9604 (ClinicalTrials.gov search) |
| It stimulates lipolysis | Mixed | Mixed. The 177-191 peptide stimulated lipase in rat fat tissue and raised lipolysis in human fat in a dish, and AOD-9604 raised blood glycerol in mice, but in rat fat pads 177-191 did not raise glycerol release significantly (Ng et al., 2000 (AOD9401); Heffernan et al., 2000; Heffernan et al., 2001 (mice); Wu and Ng, 1993) |
| It leaves blood sugar and insulin alone | Mixed | Mixed. In normal rats 176-191 raised blood glucose and insulin and cut insulin sensitivity at 5 nmol/kg, and 177-191 lowered glucose uptake in fat cells. Long treatment with 177-191 or AOD-9604 in obese rodents caused no insulin resistance (Ng and Bornstein, 1978; Wijaya and Ng, 1993; Ng et al., 2000 (AOD9401); Ng et al., 2000 (AOD9604)) |
| It does not act like growth hormone | Mixed | Mixed. In mice AOD-9604 did not bind the growth hormone receptor or make cells multiply. We found no such test of the native fragment (Heffernan et al., 2001 (mice)) |
| HGH fragment 176-191 is the same as AOD-9604 | Contradicted | No. AOD-9604 has a tyrosine where 176-191 has a phenylalanine, and the two have different registry numbers and weights (PubChem; PubChem) |
| It has been tested in people | Contradicted | We found no study of the native fragment. AOD-9604 was tested in about 900 people and in three pain trials, with weight loss under 1 kg (2.2 lb) beyond placebo in the largest trial (Stier et al., 2013; company announcement, 2007) |
| It fights breast cancer | Untested | One cell study. Nanoparticles with the peptide, whose sequence was AOD-9604’s, were toxic to cells at a lower dose than doxorubicin alone. No animal or human study (Habibullah et al., 2022) |
| It lasts only minutes in the body | Untested | We found no measurement of how long it lasts in animals or people. The only stability data are of samples kept in a dish (Mazzarino et al., 2026; Dominikowski et al., 2026) |
| HGH fragment 176-191 is FDA-approved | Contradicted | No. We found no Drugs@FDA application and no drug listing under that name (openFDA; openFDA NDC) |
| Research-grade HGH fragment contains the amount on the label | Untested | We found no analysis of this product. A study of falsified peptide drugs found purity of 5% to 75% for peptides with cysteines, which the fragment has (Janvier et al., 2018) |
| It is banned in sport | Supported | Yes. The 2026 WADA list, section S2.2.3, names hGH 176-191 and AOD-9604, prohibited at all times (WADA, 2026) |
Verdict key. Supported: controlled data in people, or the official record, back it. Mixed: studies disagree, or the support is small or limited to one use. Untested: we found no study in people. Contradicted: the studies or record we found show no effect or the opposite.
What the studies used
| Study | What was tested | Amount and route |
|---|---|---|
| Ng and Bornstein, 1978 | Normal rats | 5 nmol/kg of body weight, one dose, for the insulin tolerance test |
| Ng et al., 2000 (AOD9604) | Obese Zucker rats, AOD-9604 | 500 µg/kg a day by mouth for 19 days |
| Heffernan et al., 2000 | Obese ob/ob mice, AOD-9401 | By mouth for 30 days |
| Heffernan et al., 2001 (mice) | Obese and lean mice | Mini-osmotic pumps for 14 days |
| Kwon and Park, 2015 | Rabbit knees, AOD-9604 | 0.25 mg into the knee joint weekly |
Every amount above is an animal amount. We found no human dose of the native fragment, and the human trials above used AOD-9604 pills, single doses into a vein and infusions. Nothing here is a dosing recommendation, and we don’t repeat vial sizes or cycle lengths from seller pages.
Legal and approval status
- Not approved. We found no Drugs@FDA application for HGH fragment 176-191 or AOD-9604, and no drug listing under the names “hGH fragment” or “176-191”. The FDA’s drug directory lists AOD-9604 powders as bulk ingredients, which isn’t an approval (openFDA; openFDA NDC).
- Compounding. The FDA’s risk page, current as of April 22, 2026, names AOD-9604. Neither hGH 176-191 nor AOD-9604 is named in the FDA’s list of bulk substances nominated for compounding under section 503A, updated May 14, 2026 (FDA page; FDA document). We did not research whether pharmacies may lawfully compound it.
- Not in the HHS policy. The October 2026 temporary policy covers six other peptides, not this one (Reuters, 2026).
- Other countries. We did not check how other countries regulate it.
- Research-use vials. Products labeled “research use only” aren’t approved for use in people.
- Sport. The World Anti-Doping Agency’s 2026 list, section S2.2.3, names growth hormone fragments, including AOD-9604 and hGH 176-191, prohibited at all times (WADA, 2026).
What to look for if you research it
We don’t name or link sellers. These checks come from the studies and from the FDA:
- Which peptide. Ask for the sequence and mass. 176-191 is FLRIVQCRSVEGSCGF at 1,799.1 g/mol, AOD-9604 is YLRIVQCRSVEGSCGF at 1,815.1, and 177-191 is 1,651.9. A listing that gives the wrong registry number may be the wrong peptide.
- “Clinical trials.” The trials were of AOD-9604, and the largest beat placebo by under 1 kg (2.2 lb). None tested the native fragment.
- “No effect on blood sugar.” The earliest test of 176-191 in rats found the opposite. The later no-effect results came from long treatment of obese rodents with 177-191 and AOD-9604.
- “Burns belly fat.” No study looked at belly fat in people.
- “Cycle length” and dose. No study gave a person a dose or a schedule. The animal amounts are per kilogram of a rat.
- “99% pure.” Ask for a batch report that checks the sequence and mass. Falsified peptide drugs have been found at 5% to 75% purity.
- Competition. The 2026 WADA list names it.
Our guide to what to look for explains what each test on a lab report proves and which routes are legal; how to read a peptide study explains how to judge the studies sellers cite.
Trials under way
We found no trial of HGH fragment 176-191 or AOD-9604 that is recruiting or active, so there is nothing to list on our recruiting or in-progress pages. ClinicalTrials.gov searches on November 16, 2026 found no record for “176-191”, “hGH fragment” or AOD9604, and three completed pain trials under the name LAT8881, covered on the AOD-9604 page (search). The 2001 to 2006 obesity trials predate most registry records. A registry search isn’t proof that no unregistered study exists.
What’s still unknown
- Whether the native 176-191 fragment does anything for fat loss in people; we found no study that gave it to anyone.
- What it does to blood sugar and insulin in people, given the 1978 rat findings.
- Whether results with 177-191 and AOD-9604 apply to 176-191, which differs by one amino acid at the front.
- How long it lasts in the body; we found no measurement.
- What is in the vials sold as HGH fragment 176-191 now; we found no analysis of them.
Retracted and flagged studies
A retracted study has been pulled by its journal, usually for serious errors or misconduct, and its results shouldn’t be relied on. A withdrawn paper was pulled, often before final publication. An expression of concern means the journal has flagged a problem it is still looking into.
We check every study this page cites against PubMed and the Retraction Watch database, and search both for flagged studies that mention HGH fragment 176-191. We recheck every month. Last checked Nov 16, 2026.
We found no retracted, withdrawn or flagged studies that mention HGH fragment 176-191.
Studies this page relies on
| Study | Published in | Status |
|---|---|---|
| Wade et al., 1979 | Int J Pept Protein Res | No retraction or concern |
| Ng and Bornstein, 1978 | Am J Physiol | No retraction or concern |
| Natera et al., 1994 | Biochem Mol Biol Int | No retraction or concern |
| Wijaya and Ng, 1993 | Biochem Mol Biol Int | No retraction or concern |
| Wu and Ng, 1993 | Biochem Mol Biol Int | No retraction or concern |
| Heffernan et al., 2000 | Am J Physiol Endocrinol Metab | No retraction or concern |
| Ng et al., 2000 | J Mol Endocrinol | No retraction or concern |
| Ng et al., 2000 | Horm Res | No retraction or concern |
| Ogru et al., 2000 | J Pept Res | No retraction or concern |
| Heffernan et al., 2001 | Int J Obes Relat Metab Disord | No retraction or concern |
| Heffernan et al., 2001 | Endocrinology | No retraction or concern |
| Cox et al., 2015 | Drug Test Anal | No retraction or concern |
| Kwon and Park, 2015 | Ann Clin Lab Sci | No retraction or concern |
| Janvier et al., 2018 | Talanta | No retraction or concern |
| Habibullah et al., 2022 | Drug Des Devel Ther | No retraction or concern |
| Mazzarino et al., 2026 | Analyst | No retraction or concern |
| Dominikowski et al., 2026 | Front Endocrinol (Lausanne) | No retraction or concern |
Bring your questions to other researchers
Our forum opens once 100 researchers join the waitlist. Members post studies, ask what they actually found, and answer with sources.
Questions
What is HGH fragment 176-191?
What is HGH fragment 176-191 used for?
Sellers market it for fat loss. We found no study of the native fragment in people. In 1978 it raised blood glucose and insulin in normal rats, and later work on 177-191 and AOD-9604 in obese rodents found less weight gain (Ng and Bornstein, 1978; Natera et al., 1994; Ng et al., 2000 (AOD9604)).
Is HGH fragment 176-191 the same as HGH?
No. Human growth hormone is a protein of 191 amino acids. The fragment is its last 16, made as a separate peptide (UniProt).
Is HGH fragment 176-191 the same as AOD-9604?
No, but they are close. AOD-9604 is 177-191 with a tyrosine added at the front, so it differs from 176-191 only in its first amino acid. The two have different registry numbers (Cox et al., 2015; PubChem; PubChem).
Will HGH fragment 176-191 remove belly fat?
We found no study of belly or visceral fat in people given the fragment or AOD-9604. The largest AOD-9604 trial beat placebo by less than 1 kg, or 2.2 lb, over 24 weeks (company announcement, 2007).
What are the side effects of HGH fragment 176-191?
We found no human side-effect data for the native fragment. In normal rats it raised blood glucose and insulin and cut insulin sensitivity (Ng and Bornstein, 1978).
Does HGH fragment 176-191 raise blood sugar?
In normal rats, yes: the 176-191 peptide raised blood glucose briefly and insulin for longer, and cut insulin sensitivity at 5 nmol/kg. Long treatment of obese rodents with 177-191 or AOD-9604 caused no insulin resistance (Ng and Bornstein, 1978; Ng et al., 2000 (AOD9401); Ng et al., 2000 (AOD9604)).
Does HGH fragment 176-191 raise IGF-1?
We found no study of the native fragment. In mice AOD-9604 did not bind the growth hormone receptor, and the company’s human safety summary reports no significant IGF-1 differences (Heffernan et al., 2001 (mice); Stier et al., 2013).
What dose of HGH fragment 176-191 did the studies use?
Only animal amounts: for example 5 nmol/kg in rats in 1978, and 500 µg/kg a day of AOD-9604 by mouth in obese rats. There is no human dose. See what the studies used. It is not a dosing recommendation (Ng and Bornstein, 1978; Ng et al., 2000 (AOD9604)).
How long does HGH fragment 176-191 last in the body?
We found no measurement. Samples of both the fragment and AOD-9604 degraded extensively after a week in serum or plasma at 4 or 22 °C, which is about storing samples, not the body (Mazzarino et al., 2026).
How is HGH fragment 176-191 different from tesamorelin?
They are different kinds of compound. Tesamorelin is an FDA-approved drug that makes the pituitary release growth hormone; the fragment is a piece of the hormone and has no human study. See what the research shows on tesamorelin.
Is HGH fragment 176-191 FDA-approved?
No. We found no Drugs@FDA application and no drug listing under that name (openFDA; openFDA NDC).
Is HGH fragment 176-191 banned in sport?
Yes. The 2026 WADA list, section S2.2.3, names hGH 176-191 and AOD-9604, prohibited at all times (WADA, 2026).
Are there HGH fragment 176-191 clinical trials recruiting?
We found none. ClinicalTrials.gov has no record for the fragment or AOD9604, and three completed pain trials under the name LAT8881 (search, November 16, 2026).
Sources
- Ng FM, Bornstein J. Hyperglycemic action of synthetic C-terminal fragments of human growth hormone. Am J Physiol. 1978;234(5):E521-6. PubMed 645904
- Wade JD, Ng FM, Bornstein J. Diabetogenic action of human growth hormone. Synthesis and activity of C-terminal fragments. Int J Pept Protein Res. 1979;13(2):195-200. PubMed 429095
- Wu Z, Ng FM. Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone. Biochem Mol Biol Int. 1993;30(1):187-96. PubMed 8358331
- Wijaya E, Ng FM. Effect of an antilipogenic fragment of human growth hormone on glucose transport in rat adipocytes. Biochem Mol Biol Int. 1993;31(3):543-52. PubMed 8118430
- Natera SH, Jiang WJ, Ng FM. Reduction of cumulative body weight gain and adipose tissue mass in obese mice: response to chronic treatment with synthetic hGH 177-191 peptide. Biochem Mol Biol Int. 1994;33(5):1011-21. PubMed 7987248
- Ogru E, Wilson JC, Heffernan M, et al. The conformational and biological analysis of a cyclic anti-obesity peptide from the C-terminal domain of human growth hormone. J Pept Res. 2000;56(6):388-97. PubMed 11152298
- Ng FM, Jiang WJ, Gianello R, et al. Molecular and cellular actions of a structural domain of human growth hormone (AOD9401) on lipid metabolism in Zucker fatty rats. J Mol Endocrinol. 2000;25(3):287-98. PubMed 11116208
- Heffernan MA, Jiang WJ, Thorburn AW, et al. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol Endocrinol Metab. 2000;279(3):E501-7. PubMed 10950816
- Ng FM, Sun J, Sharma L, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-8. PubMed 11146367
- Heffernan MA, Thorburn AW, Fam B, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001;25(10):1442-9. PubMed 11673763
- Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-9. PubMed 11713213
- Kwon DR, Park GY. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci. 2015;45(4):426-32. PubMed 26275694
- Habibullah MM, Mohan S, Syed NK, et al. Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells. Drug Des Devel Ther. 2022;16:1963-1974. PubMed 35783198
- Cox HD, Smeal SJ, Hughes CM, et al. Detection and in vitro metabolism of AOD9604. Drug Test Anal. 2015;7(1):31-8. PubMed 25208511
- Mazzarino M, Colpaert T, Deventer K, et al. Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices. Analyst. 2026;151(15):4398-4413. PubMed 42328738
- Janvier S, Cheyns K, Canfyn M, et al. Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market. Talanta. 2018;188:795-807. PubMed 30029448
- Dominikowski A, Rękoś Z, Olejarz M, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026;17:1822475. PubMed 42395176
- Stier H, Vos E, Kenley D. Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. J Endocrinol Metab. 2013;3(1-2):7-15. Journal page
- Metabolic Pharmaceuticals Limited. Metabolic’s obesity drug - Phase 2B clinical trial results. ASX announcement, February 21, 2007. Announcement
- ClinicalTrials.gov. Searches for “176-191”, “hGH fragment”, AOD9604, AOD-9604 and “growth hormone fragment”, November 16, 2026: no record; three completed pain trials under the name LAT8881 (NCT03865953, NCT04153409, NCT05298306). Search
- World Anti-Doping Agency. 2026 Prohibited List, section S2.2.3 (growth hormone fragments, including AOD-9604 and hGH 176-191). WADA document
- U.S. Food and Drug Administration. openFDA Drugs@FDA: searches for hGH fragment and AOD-9604 found no application, November 16, 2026. openFDA
- U.S. Food and Drug Administration. openFDA drug listings (NDC): no listing under “hGH fragment” or “176-191”; AOD-9604 powders are listed as bulk ingredients, November 16, 2026. openFDA NDC
- U.S. Food and Drug Administration. Safety risks associated with certain bulk drug substances nominated for use in compounding (content current as of April 22, 2026; AOD-9604 named, hGH 176-191 not named). FDA page
- U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A: categories, updated May 14, 2026 (neither AOD-9604 nor hGH 176-191 named). FDA document
- Reuters. U.S. health department to allow temporary sale of some unapproved peptides. October 28, 2026. Article
- UniProt. Somatotropin, human (P01241): the 191-amino-acid hormone (residues 27 to 217 of the precursor) and its disulfide bonds. UniProt
- National Library of Medicine. PubChem compound record: hGH fragment 176-191 (starts with F) (CID 16131230). PubChem
- National Library of Medicine. PubChem compound record: hGH fragment 177-191 (AOD-9401) (CID 25078169). PubChem
- U.S. Food and Drug Administration. Global Substance Registration System: AOD-9604 (UNII 7UP768IP4M). GSRS
Last reviewed Nov 16, 2026. Approval and compounding status change often; we recheck this page when they do. Nothing here is medical advice; see our medical disclaimer. Found a mistake? Email editors@peptideresearchstudy.com.